@eijwj - I think you are right but my understanding is most of the obvious conditions as it relates to Exenatide are currently under patent with other groups. Space maybe the exception, but if I am honest I struggle to see how this would be a commercial opportunity, that said it is probably a carried interest, as all the development will be grant funded.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-36
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 84879 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 12400 | 3 |
View Market Depth
| Last trade - 10.12am 11/11/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable